Clinical trials: Squamous Cell Carcinoma of the Hypopharynx
HNSCC, Lip SCC
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembrolizumab and cetuximab for patients with recurrent/metastatic HNSCC.
- Conditions
- HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT03082534
- Testing
- Pembrolizumab, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of California, San Diego
Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Hypopharynx
Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial
This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy…
- Trial name
- STELLAR (NCT05752149)
- Testing
- CRGD-ZW800-1
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Erasmus Medical Center
Squamous Cell Carcinoma of Hypopharynx, Squamous Cell Carcinoma of Larynx
Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
Patients undergoing concurrent chemoradiotherapy (CCRT) for head and neck squamous cell carcinoma frequently experience treatment-related toxicities including mucositis, dysphagia, acute kidney injury, pain, constipation…
- Conditions
- Squamous Cell Carcinoma of Hypopharynx, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT07784855
- Testing
- Scheduled IV Hydration, Clinician Assessment-Based IV Hydration
- Where
- 6 sites in United States
- Volunteers
- 180 people
- Sponsor
- West Virginia University
Oropharynx Cancer, Oral Cancer
Very Intense Radiotherapy-chemotherapy Regimen in Advanced HNSCC
Altered fractionated radiotherapy and concomitant radio-chemotherapy have been shown to be two possibilities for improving efficacy of radiotherapy in locally advanced head and neck carcinomas.
- Conditions
- Oropharynx Cancer, Oral Cancer, Hypopharynx Cancer, Larynx Cancer
- Trial name
- NCT00162708
- Testing
- Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID), Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID), CDDP, 5 Fu
- Where
- 3 sites in France
- Volunteers
- 120 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of the Hypopharynx
Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
Analysis of tumor tissue (which is already available in pathology) and collection of saliva/stool and blood samples, which are obtained as part of a routine collection.
- Conditions
- Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of the Hypopharynx, Larynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- DoIT_Neck (NCT06947668)
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Head Neck Cancer, Metastatic Squamous Cell Carcinoma
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
The purpose of this research is to see what effects the treatment regimen chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab), has on patients who have been diagnosed with head/neck squamous cell…
- Conditions
- Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma
- Trial name
- NCT04858269
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Wake Forest University Health Sciences
Oral Squamous Cell Carcinoma, Squamous Cell Carcinoma of Oropharynx
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
The purpose of the study is to assess in a randomized, double blind, controlled, multi-center, phase III study, the efficacy of low level diode laser (100 MW, 658 Nm), in the prevention and treatment of radiochemotherapy-induced…
- Conditions
- Oral Squamous Cell Carcinoma, Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of Hypopharynx, Oral Mucositis
- Trial name
- LaserMucite (NCT01772706)
- Testing
- low level laser therapy
- Where
- 6 sites in France
- Volunteers
- 97 people
- Sponsor
- Institut Cancerologie de l'Ouest
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
This phase II trial studies how well sorafenib works with carboplatin and paclitaxel in treating participants with head and neck squamous cell cancer that has spread to other parts of the body or that has come back.
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity
- Trial name
- NCT00494182
- Testing
- Carboplatin, Paclitaxel, Sorafenib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
The purpose of this study is to find out if the combination of two established anti-cancer therapies are beneficial in participants with Head and Neck Squamous Cell Carcinoma (HNSCC).
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT03370276
- Testing
- Nivolumab, Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
This randomized, prospective, multicenter phase II/III trial will study the reduction of radiation volume by eliminating radiotherapy (RT) to the elective neck using strictly defined surgical and radio-oncological standards to…
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Oropharynx
- Trial name
- DIREKHT2 (NCT06030440)
- Testing
- Eliminating RT to the elective neck, RT standard of care
- Where
- Germany
- Volunteers
- 508 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of Head and Neck, Sinus Cancer
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer
- Trial name
- NCT07063212
- Testing
- Sacituzumab Govitecan, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
This pilot clinical trial studies transoral robotic surgery (TORS) in treating patients with benign or malignant tumors of the head and neck.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT01473784
- Testing
- transoral robotic surgery, quality of life assessment
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.
The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative…
- Conditions
- Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- HN1901 (NCT04445064)
- Testing
- IO102, IO103
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
The purpose of this study is to see if the IRX-2 regimen and Durvalumab, will have a tolerable safety profile and will increase the intratumoral immune profile compared with the pretreatment tumors.
- Conditions
- Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT03381183
- Testing
- Durvalumab, IRX-2 Regimen
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Laryngeal Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma
Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.
Rationale | Elective neck irradiation is performed in head and neck cancer patients treated with definitive (chemo)radiotherapy. The aim is to eradicate nodal metastases that are not detectable by pretreatment imaging techniques.
- Conditions
- Laryngeal Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- PRIMO (NCT05333523)
- Testing
- Sentinel lymph node biopsy guided selective elective neck irradiation, Standard elective neck irradiation
- Where
- 9 sites in Netherlands
- Volunteers
- 242 people
- Sponsor
- Radboud University Medical Center
Head and Neck Cancer, Squamous Cell Carcinoma
Pembrolizumab in Combination With CRT for LA-SCCHN
This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemoradiotherapy (CRT) in patients with stage III-IVB squamous cell carcinoma of the…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT02586207
- Testing
- pembrolizumab (MK-3475), Cisplatin, Radiation
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanford Health
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
This pilot research trial studies circulating tumor deoxyribonucleic acid (DNA) in predicting outcomes in patients with stage IV head and neck cancer or stage III-IV non-small cell lung cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT02245100
- Testing
- Cytology specimen, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
The purpose of this study is to learn more about a drug called Vorinostat (an experimental drug) in combination with chemoradiation.
- Conditions
- HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx
- Trial name
- HPV (NCT05608369)
- Testing
- Cisplatin, Radiation therapy, Vorinostat
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center